Profusa Lags Rivals in Key Metrics, Analysts Say

Profusa faces challenges compared to competitors in the 'Surgical, Medical, And Dental Instruments And Supplies' industry

Published on Feb. 22, 2026

Got story updates? Submit your updates here. ›

Profusa (NASDAQ:PFSA) is one of 29 publicly-traded companies in the 'Surgical, Medical, And Dental Instruments And Supplies' industry, but it lags behind its rivals in key metrics like revenue, earnings, institutional ownership, and stock volatility, according to a new analysis. Analysts believe Profusa has less favorable growth aspects than its competitors in the industry.

Why it matters

As a public company, Profusa's performance and competitive positioning are important factors for investors to consider. The analysis highlights areas where Profusa is underperforming compared to its industry peers, which could impact the company's long-term growth prospects.

The details

The analysis found that Profusa's rivals have higher revenue and lower earnings than Profusa, but are trading at a higher price-to-earnings ratio, indicating they are seen as having more favorable growth potential. Profusa also has lower institutional and insider ownership compared to its competitors, as well as a lower beta suggesting its stock is less volatile than the industry average.

  • The analysis was published on February 18, 2026.

The players

Profusa

A publicly-traded company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry.

NorthView Acquisition Corporation

A subsidiary of NorthView Sponsor I, LLC that intends to focus its search on businesses in the healthcare sector.

Got photos? Submit your photos here. ›

The takeaway

Profusa's underperformance compared to its industry peers in key areas like revenue, earnings, institutional ownership, and stock volatility suggests the company may face challenges in maintaining a competitive edge and driving long-term growth. Investors will likely be closely watching Profusa's efforts to address these gaps.